About: http://webisa.webdatacommons.org/444557254

Property	Value
http://www.w3.org/1999/02/22-rdf-syntax-ns#type	http://www.w3.org/ns/prov#Entity
http://www.w3.org/ns/prov#value	Though both bevacizumab and ranibizumab were used in this case, the reason for doing so was mainly due to ease of availability and licensing issues and we do not claim any beneficial effect of one over the other.
http://www.w3.org/ns/prov#wasQuotedFrom	retinalphysician.com